Alzamend Neuro Inc Stock Price, News & Analysis

Ault Alliance has announced that Alzamend Neuro has initiated its Phase I/IIA clinical trial for the immunotherapeutic vaccine ALZN002 targeting Alzheimer’s. This trial aims to establish the appropriate dosage for patients before a larger Phase IIB trial, expected within three months post-data collection. Ault Alliance holds approximately 11.3 million shares of Alzamend and has rights to acquire more, potentially bringing its total ownership to 23.8 million shares, or 22% of Alzamend's outstanding stock. The company emphasizes continued support for Alzamend's mission against Alzheimer’s disease.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has initiated a Phase I/IIA clinical trial for its immunotherapy vaccine ALZN002, aimed at treating mild to moderate Alzheimer's dementia. The trial seeks to evaluate the safety, tolerability, and efficacy of ALZN002 against a placebo, involving 20-30 subjects. The primary objective is to identify the suitable dosage for a larger Phase IIB trial, planned to launch within three months post-data collection. ALZN002, derived from patients' immune cells, targets amyloid-beta proteins associated with Alzheimer's, potentially offering a safer, less frequent treatment method. Pre-clinical studies show promising results with no adverse effects reported.

Alzamend Neuro, Inc. (NASDAQ: ALZN), focusing on Alzheimer's disease and other disorders, has received a "Study May Proceed" letter from the FDA for its ALZN002 immunotherapy. This approval allows the company to initiate a Phase I/IIA clinical trial for treating mild to moderate dementia related to Alzheimer's. ALZN002, a patient-specific immunotherapy, aims to enhance the immune response against amyloid-beta proteins, potentially altering disease progression. Initial dosing is expected in Q1 2023. The IND application is supported by pre-clinical studies indicating safety and significant amyloid reductions in animal models.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has completed the clinical portion of its Phase IIA multiple ascending dose study evaluating AL001, a novel lithium-delivery system aimed at treating dementia related to Alzheimer’s disease. This study assessed the safety and tolerability of AL001 in both healthy subjects and patients with mild to moderate Alzheimer’s. The technology is designed to mitigate the side effects typically associated with lithium treatments. Topline data is expected to be reported in June 2023, which will inform further clinical developments for treating various cognitive disorders including bipolar disorder, major depressive disorder, and PTSD.